#CVS Reverses Two Decades of Deal-Making
CVS Health is breaking itself in two. On November 4 the company announced plans to separate its roughly 9,000 retail pharmacies from its insurance and drug benefits arm, aiming to create two publicly traded companies by the first half of 2028, subject to final board approval and other conditions [1]. Existing shareholders would hold stock in both.
The new CVS Health would keep Aetna, the Caremark pharmacy benefit manager, Oak Street Health, Signify Health and the specialty drug business, led by CEO David Joyner. CVS Pharmacy would take the stores, mail-order pharmacy and walk-in clinics under Prem Shah. Joyner says each business will be more nimble on its own, with shared services kept going through commercial agreements.
The plan unwinds a strategy two decades in the making. CVS merged with Caremark in 2007 and paid $78 billion for Aetna in 2018, arguing that owning the pharmacy, the insurer and the drug benefits manager under one roof would make healthcare simpler and cheaper.
#A Split From a Position of Strength
The timing is deliberate. CVS has spent the past two years repairing Aetna after medical costs ran well ahead of forecasts, cutting about $2 billion in costs and closing stores along the way. That work is now showing in the numbers. Third quarter profit came in at $2.2 billion on $108.4 billion of revenue, against a $4 billion loss a year earlier, and the company raised its 2026 outlook.
That gives management a stronger hand. A focused insurer and a standalone pharmacy chain are easier for investors to value than one sprawling group, and each can set its own priorities for spending and shareholder returns.
A sharper way to see the markets in just 5 minutes.
Same news, different lens. We cut through the noise and hand you the overlooked ideas and the deeper read the crowd misses. Join 38,000+ investors seeing the markets differently.
#Politics Hangs Over the Break-Up
Joyner denies that regulation drove the decision, but the backdrop is hard to ignore. Lawmakers in both parties have targeted companies that own both pharmacies and pharmacy benefit managers. A bipartisan federal bill is on the table, and CVS is fighting state laws in Arkansas and Tennessee that would bar that kind of common ownership. With Democrats taking control of Congress in January, that scrutiny is expected to continue. One Leerink analyst suggested the split could help CVS sidestep state-level pressure.
#Why the Market Flinched
Investors were not convinced on day one. CVS shares fell 12.5% on November 4, wiping nearly $15 billion from the company's market value [2]. Break-ups are expensive, slow and distracting, and a timeline that runs into 2028 leaves plenty of room for things to change.
The bigger question is how the pharmacy business fares alone. Without Aetna and Caremark steering prescriptions its way, a store chain has to compete on thin margins. The insurer keeps the profit engine, but also the exposure to rising medical costs that caused its recent troubles.
For shareholders, the payoff depends on whether the two parts end up valued more highly than the whole. Watch for details on how debt will be divided, what the commercial agreements between the two companies look like, and whether Congress moves on pharmacy benefit manager reform before the split completes.